Dotinurad (Urece) is a drug for the treatment of gout and hyperuricemia.[1][2] It was developed by Fuji Yakuhin and approved for use in Japan in 2020.[2][3] The drug is continuing clinical trials by Fortress Biotech and regulatory evaluation for approval in North America and Europe.[3][4]
Clinical data | |
---|---|
Trade names | Urece |
Other names | FYU-981 |
Legal status | |
Legal status |
|
Identifiers | |
| |
CAS Number | |
PubChem CID | |
DrugBank | |
ChemSpider | |
UNII | |
KEGG | |
ChEMBL | |
Chemical and physical data | |
Formula | C14H9Cl2NO4S |
Molar mass | 358.19 g·mol−1 |
3D model (JSmol) | |
| |
|
Dotinurad acts as a selective urate reabsorption inhibitor that has uric acid lowering activity by inhibiting URAT1/SLC22A12 receptor. It is a structural analog of Benzbromarone. [5][6]
References
edit- ^ Kuriyama S (March 2020). "Dotinurad: a novel selective urate reabsorption inhibitor as a future therapeutic option for hyperuricemia". Clinical and Experimental Nephrology. 24 (Suppl 1): 1–5. doi:10.1007/s10157-019-01811-9. PMC 7066308. PMID 31754883.
- ^ a b "List of Approved Products" (PDF). Pharmaceuticals and Medical Devices Agency.
- ^ a b "Fortress takes on dotinurad in USA and Europe". November 5, 2020. Retrieved June 23, 2021.
- ^ "Fortress Biotech Announces Exclusive License Agreement With Fuji Yakuhin to Develop Dotinurad in North America and Europe". May 10, 2021. Retrieved June 23, 2021.
- ^ Taniguchi T, Ashizawa N, Matsumoto K, Saito R, Motoki K, Sakai M, et al. (October 2019). "Pharmacological Evaluation of Dotinurad, a Selective Urate Reabsorption Inhibitor". The Journal of Pharmacology and Experimental Therapeutics. 371 (1): 162–170. doi:10.1124/jpet.119.259341. PMID 31371478. S2CID 199382932.
- ^ Uda J, Kobashi S, Miyata S, Ashizawa N, Matsumoto K, Iwanaga T (October 2020). "Discovery of Dotinurad (FYU-981), a New Phenol Derivative with Highly Potent Uric Acid Lowering Activity". ACS Medicinal Chemistry Letters. 11 (10): 2017–2023. doi:10.1021/acsmedchemlett.0c00176. PMC 7549256. PMID 33062187.